Last updated: February 15, 2026
Overview
NDC 00093-7385 is a pharmaceutical product marketed by Medtronic as the Infuse Bone Graft with specific indications in orthopedics and spinal surgery. Its primary ingredients include recombinant human bone morphogenetic protein-2 (rhBMP-2), used to stimulate bone growth.
Market Size and Adoption
Market dimensions:
- The global spinal fusion market was valued at approximately $6.7 billion in 2021.
- The North American segment accounts for roughly 50-60% of the total, driven by high adoption rates and advanced healthcare infrastructure.
Key drivers:
- Aging population: Growing incidence of degenerative spine conditions.
- Surgical preferences: Shift toward biologic solutions over autograft procedures.
- Regulatory approvals: FDA approval for specific indications, expanding market access.
Usage patterns:
- The product sees widespread use in adult spinal deformity, complex degenerative conditions, and revision surgeries.
- Adoption levels vary by country; North America leads with approximately 60-70% market share, followed by Europe and Asia-Pacific regions.
Competitive Landscape
Major competitors include:
| Company |
Product |
Market Share |
Notes |
| Medtronic |
Infuse Bone Graft |
~40% |
Widely used in spinal indications |
| Stryker |
OP-1 Putty |
Smaller share |
Primarily markets in Europe |
| NuVasive |
i-FACTOR Graft |
Growing |
Less established globally |
| Globally |
Various recombinant BMP products |
Niche players |
Regulatory restrictions vary |
Price Analysis
Pricing structure:
- The wholesale acquisition cost (WAC) for a typical 4.2 mg dose of Infuse ranges from $2,500 to $4,200 per unit.
- The average cost per use (including surgical supplies and hospital charges) is approximately $8,000 to $15,000.
Historical pricing trends:
- Prices have remained relatively stable from 2015-2022, with minor fluctuations due to market dynamics and regulatory changes.
- Price pressures from generic and biosimilar entrants are minimal because of patent protections and manufacturing complexities.
Patent and regulatory barriers:
- Key patents covering recombinant BMP-2 formulations extend until at least 2024, limiting biosimilar entry.
- FDA approvals for specific indications and delivery methods influence pricing power.
Price Projections (Next 5 Years)
| Year |
Estimated Price Range per Unit |
Key Factors |
| 2023 |
$2,500 - $4,200 |
Patent protections in effect |
| 2024 |
$2,600 - $4,300 |
Potential patent expiry or litigation |
| 2025 |
$2,700 - $4,500 |
Entry of biosimilars if patents expire |
| 2026 |
$2,800 - $4,600 |
Increased competition, price negotiations |
| 2027 |
$2,900 - $4,700 |
Market maturation, biosimilar presence |
Risks and Opportunities
Risks:
- Patent cliffs post-2024 could reduce prices and market exclusivity.
- Regulatory restrictions on off-label uses and safety concerns may impact adoption.
- Introduction of biosimilars could decrease prices by 10-30%, depending on regional regulatory pathways.
Opportunities:
- Expansion into new indications, such as trauma or craniofacial reconstruction.
- Geographic expansion into emerging markets with growing healthcare investment.
- Incremental patent extensions or complementary product innovations.
Summary
The Infuse Bone Graft’s market remains sizable with stable prices due to patent protections and high adoption in spine surgery. Prices are projected to remain relatively flat until patent expiration or biosimilar entry, which could introduce downward pressure. The product stands to benefit from ongoing growth in spine procedures and orthopedic surgeries, but key patent expirations from 2024 onward will require strategic adaptation.
Key Takeaways
- The global spinal fusion market was valued at $6.7 billion in 2021, with North America leading.
- Current prices for NDC 00093-7385 range from $2,500 to $4,200 per dose.
- Prices are stable until patent expiry, projected around 2024, after which biosimilars may enter.
- Market share remains concentrated among a few players, guiding pricing power.
- Regulatory, patent, and competitive factors will shape future pricing and adoption.
FAQs
1. How does patent protection impact the price of NDC 00093-7385?
Patents protect exclusivity, allowing Medtronic to set higher prices. Post-2024, patent expiry could lead to biosimilar entry, increasing competition and reducing prices.
2. Are biosimilars likely to be approved for this product?
Biosimilar approval depends on regional regulatory pathways; some regions may approve biosimilars around 2024-2025, potentially lowering prices.
3. What is the expected market growth rate for this drug?
The spinal fusion market is projected to grow at a compound annual growth rate (CAGR) of approximately 5-7% through 2030.
4. Which regions are poised for increased adoption?
Emerging markets in Asia-Pacific and Latin America are expected to see increased adoption due to rising healthcare investment.
5. How might safety concerns impact future sales?
Regulatory scrutiny over adverse effects could restrict off-label uses and limit sales growth, especially if safety profiles are questioned.
Sources:
- MarketsandMarkets, "Spinal Fusion Devices Market," 2022.
- U.S. FDA, "NDA Approvals," 2022.
- Medtronic Annual Reports, 2021-2022.
- IQVIA, "Global Orthopedic Market Data," 2022.
- ClinicalTrials.gov, "BMP-2 Product Trials," accessed February 2023.
